Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Patients will pay no more than $35 a month. Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

We recently compiled a list of the Billionaire Ken Fisher’s Top 10 High Growth Stock Picks. In this article, we are going to ...

Sales of type 2 diabetes drug Ozempic jumped in 2024 by over a quarter to DKK120.3billion, as human insulin revenues increased by 15 per cent to DKK55.4billion. Consequently, Novo Nordisk's ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too ... having just had prices set for some of its insulin products in the past year. And the inclusion of the semaglutide drugs — Wegovy for weight ...

In addition, the company has experience with negotiations since Novo Nordisk has already gone through a similar process with its insulin products. The U.S. government started negotiating prices ...